1Progress in clinical trials of cell transplantation for the treatment of spinal cord injury: how many questions remain unanswered?Xu-Chang Hu，Yu-Bao Lu，Yong-Na Yang，Xue-Wen Kang，Yong-Gang Wang，Bing Ma，Shuai XingReviews405-413
2Postnatal therapeutic approaches in genetic neurodevelopmental disordersGilad Levy，Boaz BarakReviews414-422
3Regulation of neuroimmune processes by damage- and resolution-associated molecular patternsAndis KlegerisReviews423-429
4Neonatal opioid exposure: public health crisis and novel neuroinflammatory diseaseVikram Vasan，Yuma Kitase，Jessie C. Newville，Shenandoah Robinson，Gwendolyn Gerner，V. Joanna Burto，Lauren L. JantzieReviews430-432
5Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical strokeHilda Martínez-Coria，Isabel Arrieta-Cruz，María-Esther Cruz，Héctor E. López-ValdésReviews433-439
6MicroRNAs as diagnostic and prognostic biomarkers of age-related macular degeneration: advances and limitationsBridget Martinez，Philip V. PeplowReviews440-447
8Microglial activation and adult neurogenesis after brain strokeIjair R.C. dos Santos，Michelle Nerissa C. Dias，Walace Gomes-LealReviews456-459
9The therapeutic potential of targeting exchange protein directly activated by cyclic adenosine 3′,5′-monophosphate (Epac) for central nervous system traumaAlba Guijarro-Belmar，Dominik Mateusz Domanski，Xuenong Bo，Derryck Shewan，Wenlong HuangReviews460-469
10Role of vitamin B12 deficiency in ischemic stroke risk and outcomeGyllian B. Yahn，Jamie E. Abato，Nafisa M. JadavjiReviews470-474
11Current scenario of the genetic testing for rare neurological disorders exploiting next generation sequencingChiara Di Resta，Giovanni Battista Pipitone，Paola Carrera，Maurizio FerrariReviews475-481
12Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctionsMonica L. Acosta，Mohd N. Mat Nor，Cindy X. Guo，Odunayo O. Mugisho，Frazer P. Coutinho，Ilva D. Rupenthal，Colin R. GreenReviews482-488
13Saccharomyces cerevisiae in neuroscience: how unicellular organism helps to better understand prion protein?Takao IshikawaReviews489-495
14Neurogenesis versus neurodegeneration: the broken balance in Alzheimer's diseaseBaruh Polis，Abraham O. SamsonPerspectives496-497
15Is serine racemase (SRR) a second hit target for LRRK2-G2019S induced Parkinson's disease?Sarah Louise Nickels，Jens Christian SchwambornPerspectives498-499
16Targeting mechanisms in cognitive training for neurodegenerative diseasesAnnalena Venneri，Riccardo Manca，Linford Fernandes，Oliver Bandmann，Matteo De MarcoPerspectives500-501
18Brain angiotensin Ⅱ in dopaminergic imbalance-derived pathologies:neuroinflammation and vascular responsesVictoria Belén Occhieppo，Osvaldo Martin Basmadjian，Claudia BregonzioPerspectives504-505
19Dysfunction of axonal transport in normal-tension glaucoma: a biomarker of disease progression and a potential therapeutic targetKazuyuki Hirooka，Tohru Yamamoto，Yoshiaki KiuchiPerspectives506-507
20Continued development of azithromycin as a neuroprotective therapeutic for the treatment of spinal cord injury and other neurological conditionsTimothy J. Kopper，John C. GenselPerspectives508-509
